ALXN - Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company that focuses on developing and commercializing life-transforming drugs for patients with rare and severe diseases. The company's main product is Soliris, a therapeutic for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Alexion Pharmaceuticals operates in two main business segments: the PNH and aHUS franchises, which include Soliris and Ultomiris, and the metabolic franchise, which includes Strensiq and Kanuma. Soliris is the company's flagship drug and is currently approved in various countries for the treatment of PNH and aHUS. Ultomiris, a follow-on drug to Soliris, is also approved for the treatment of PNH and aHUS in various countries.

In addition to its existing product portfolio, Alexion Pharmaceuticals has a robust pipeline of drugs in various stages of development. The company's research and development efforts focus on developing innovative therapies for patients with rare and severe diseases.

Alexion Pharmaceuticals has a strong financial position, with a revenue of $5.2 billion in 2020. The company has a market capitalization of over $34 billion and is listed on the NASDAQ stock exchange.

In summary, Alexion Pharmaceuticals is a leading biopharmaceutical company that focuses on developing and commercializing life-transforming drugs for patients with rare and severe diseases. With its strong product portfolio and robust pipeline of drugs, the company is well-positioned to continue its growth trajectory and deliver value to its shareholders.

Stock Sector: Drugs: Biotechnology